ZURICH, SWITZERLAND / ACCESSWIRE / November 28, 2023 / Kuros Biosciences ("Kuros" or the "Company"), a leader in next generation bone graft technologies, announced today that MagnetOs Flex Matrix has ...
MagnetOs ™ Granules becomes the third product in the MagnetOs portfolio to receive FDA clearance to market for interbody use Kuros continues expansion of the MagnetOs franchise with launch of MagnetOs ...
Schlieren (Zürich), Switzerland, August 5, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, today announced the completion of the first U.S. cases ...
Funding secured for fibrin-PTH Phase II in spinal fusion, a huge commercial opportunity First sales of MagnetOs in US and Europe, commercial roll-out on track New CFO and CMO bring solid financial and ...
MagnetOs is a bone graft like no other: thanks to its NeedleGripTM surface technology, it grows bone even in soft tissues. This surface technology provides traction for our body's vitally important ...
Kuros expects a similar sales growth trend going forward. The Company is adequately financed on its planned organic growth path and - adjusted for the Fibrin-PTH costs - will generate positive ...
SCHLIEREN (ZURICH), Switzerland, March 10, 2021 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies and a pioneer in the emerging field of ...
Medtronic will act as the exclusive sales agent of MagnetOs TM for Kuros Biosciences USA, Inc. in mutually agreed upon sales territories for use in spine surgeries Kuros will work collaboratively to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback